BMS’ Phase II trial of CAR T cell therapy meets primary endpoint
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...
Healio46m
Intervention improves timely postoperative treatment for people with head and neck cancer
A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...
Medscape27m
Underfunded, Underdiagnosed, and Misunderstood: What’s Next for Bipolar Disorder
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting ...
Pharmabiz23m
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2024, and provided ...